ResearcherShaoxing People's HospitalActive in the last 2 years

Fang Su

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4902-5191; OpenAlex author ID A5003240878. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2025: 2 papers

Papers 2

Hederagenin exerts anti-tumor effects in pancreatic cancer by impairing DRP1 mediated-mitophagy via VDAC1-HK2-PINK1/PARKIN pathway. Co-author DOI 10.1016/j.taap.2025.117586 ↗
CCL19 Suppresses Pancreatic Cancer Progression via Immune Microenvironment Remodeling: Bioinformatics and Functional Insights Co-author DOI 10.21203/rs.3.rs-7426239/v1 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Baochun Lu · 1 shared paper, 2025 · strength 0.28
- Paper Hederagenin exerts anti-tumor effects in pancreatic cancer by impairing DRP1 mediated-mitophagy via VDAC1-HK2-PINK1/PAR… DOI 10.1016/j.taap.2025.117586 ↗
Yongxia Chen · 1 shared paper, 2025 · strength 0.27
- Paper CCL19 Suppresses Pancreatic Cancer Progression via Immune Microenvironment Remodeling: Bioinformatics and Functional In… DOI 10.21203/rs.3.rs-7426239/v1 ↗
Xiao Wu · 1 shared paper, 2025 · strength 0.27
- Paper CCL19 Suppresses Pancreatic Cancer Progression via Immune Microenvironment Remodeling: Bioinformatics and Functional In… DOI 10.21203/rs.3.rs-7426239/v1 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.